Skip to main content
Premium Trial:

Request an Annual Quote

Silence Inks siRNA-Delivery Deal with Dainippon Sumitomo Pharma

Premium

Silence Therapeutics said last week that it has entered into an siRNA drug-delivery collaboration with Japanese drug firm Dainippon Sumitomo Pharma.

Under the terms of the deal, Silence will “demonstrate the functional delivery” of its proprietary siRNA molecules, in combination with its in-house AtuPlex delivery technology, to certain undisclosed targets.

Additional terms of the arrangement, including financial details, were not disclosed.

"Following extensive due diligence in the sector, we have chosen to partner with Silence Therapeutics,” Keiichi Ono, senior executive officer and executive director of drug research division of Dainippon Sumitomo Pharma, said in a statement. “We look forward to expanding this collaboration further in the future.”

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.